Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP
Derek Rose

ASX debutant aims to revolutionise prenatal screening

Identifai's testing platform can assess fetal risk across more than 280 clinically actionable genes. (Jane Dempster/AAP PHOTOS)

An Israeli company aiming to harness artificial intelligence to screen unborn babies for hundreds of genetic anomalies is set to debut on the Australian stock exchange.

Identifai Genetics will float on October 13 at a market capitalisation of $38.4 million.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.